



**Fig. S1. Gating strategy for identification of ILC2 populations, related to Fig. 1 A-C.** IL13-eGFP mice treated with 3 doses or rIL-33 (1 $\mu$ g per dose) over 1 week and culled 24h after the final dose. Cells were pre-gated on lymphoid, live (determined using a fixable live dead dye), lineage and frequencies of GFP<sup>+</sup>CD45<sup>+</sup> cells among lineage positive versus lineage negative cells was evaluated in (A). (B) ILC2 were defined by pre-gating on lymphoid, live (determined using a fixable live dead dye), GFP<sup>+</sup>CD3<sup>-</sup>NKp46<sup>-</sup> cells that were lineage (TCR $\beta$ , TCR $\gamma\delta$ , CD5, CD19, CD11b, CD11c, FC $\epsilon$ R1, GR-1, F4/80, and TER-119) negative cells and co-expressed intracellular IL-13 and surface expression of CD90.2, KLRG-1, CD127 as shown in histogram plots.